Enterprise Value
513.2M
Cash
791.5M
Avg Qtr Burn
-73.53M
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
9.15%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tremfya (guselkumab) (IL-23) Details Psoriatic arthritis, Plaque psoriasis | Approved Quarterly sales | |
Monjuvi (Tafasitamab) (CD19) Details Non-Hodgkin lymphoma, Cancer, B-cell malignancies, Chronic lymphocytic leukemia, Diffuse large B cell lymphoma | Approved Quarterly sales | |
Tafasitamab (CD19) Details Cancer, B-cell malignancies, B-cell lymphoma, Diffuse large B cell lymphoma | Phase 3 Data readout | |
Tafasitamab (CD19) Details Cancer, B-cell malignancies, Marginal zone lymphoma, Follicular lymphoma | Phase 3 Data readout | |
Pelabresib (CPI-0610) Details Myelofibrosis | Phase 3 Data readout | |
Gantenerumab Details Alzheimer's disease | Phase 3 Update | |
Tulmimetostat /CPI-0209 (EZH2 inhibitor) Details Cancer, Solid tumor/s | Phase 2 Update |